ArticleKidney3602026
Adherence to Potassium Citrate, Changes in 24-Hour Stone Risk Parameters, and Recurrent Kidney Stone Events.
Article in Kidney360, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Multi-target litholytic strategy toward calcium oxalate stone therapy: a fundamental study.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
key pointsPharmacy claims-based adherence (percentage of days covered) and urine-based adherence (change in urinary potassium excretion divided by dose) showed discordant associations with physiologic response and recurrence. Although change in urinary potassium excretion divided by dose was more strongly associated with changes in urinary citrate and pH, only percentage of days covered was significantly associated with recurrent stone events.
backgroundPatient adherence limits the effectiveness of preventive pharmacologic therapy (PPT) for urinary stone disease, highlighting the need for accurate adherence monitoring. We assessed associations between potassium citrate adherence measures, changes in 24-hour urine parameters, and the risk of recurrent stone events.
methodsIn this retrospective cohort study, we identified adult patients enrolled in Medicare with urinary stone disease, a baseline 24-hour urine collection (2010-2019), hypocitraturia or low urine pH, a prescription for potassium citrate monotherapy, and a follow-up urine collection. We defined two adherence measures: ( 1 ) percentage of days covered (PDC) using pharmacy claims and ( 2 ) change in urinary potassium between baseline and follow-up divided by medication dose (change in urinary potassium excretion divided by dose [ΔK/dose]). We assessed the association of these measures with changes in urinary citrate and pH using analysis of covariance, and the association between adherence and recurrent stone events using Cox models.
resultsAmong 793 patients meeting the study criteria, 504 (63.6%) patients were adherent on the basis of pharmacy claims (PDC ≥80%) and 389 (49.1%) patients on the basis of ΔK/dose ≥0.5. Compared with PDC ≥80%, ΔK/dose ≥0.5 had a stronger association with change in urinary citrate ( P < 0.001) and pH ( P < 0.001). Compared with PDC ≥80%, patients with PDC <80% had a higher risk of recurrent stone events (hazard ratio, 1.431; 95% confidence interval, 1.049 to 1.952), whereas ΔK/dose was not statistically significantly associated with recurrent stone events (hazard ratio, 1.032; 95% confidence interval, 0.740 to 1.439).
conclusionsThere are clinically meaningful differences in potassium citrate adherence measures. ΔK/dose was more strongly associated with the change in urinary citrate and pH. However, only PDC was significantly associated with recurrent stone events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.